Switzerland's Xigen garnered $21 million in its first round, with Tilocor Life Sciences, Venture Incubator and Initiative Capital joining as investors. Xigen has been researching a new class of peptide therapeutics for the treatment of stroke, myocardial infarction and cancer.
- read this press release for more
PLUS: Switzerland's SpinX Technologies has rounded up $12.5 million in its second round of venture capital. SpinX makes technology used to perform biological assays. The round was led by Bio Fund Management. Release